PCI further expands into New England with fill-finish upgrade in New Hampshire
A Philadelphia-based CDMO will drop $100 million into its aseptic liquid fill-finish and sterile lyophilization technology at its recently-acquired Bedford, NH campus.
PCI Pharma bought the Lyophilization Services of that New England site at the end of 2021. The new expansion will add a 50,000 square-foot facility that features a fill-finish line with a fully isolated containment system. It will have the capacity to fill 400 vials per minute, which will help PCI up its speed and get therapies to patients quicker.
The announcement is the latest in a string of moves across the world. It has expanded locations in Rockford, IL; San Diego; Melbourne, Australia and Berlin in recent years. The company will also increase capacity at sites in Spain and Wisconsin soon, the press release said.
“We are excited to introduce clients to our newest facility, which is part of our broader strategy to provide integrated end-to-end drug development, manufacturing and packaging capabilities,” CEO Salim Haffar said in a statement. “Our investment in these facilities will ensure that PCI continues to leverage new capabilities in complex formulations, aseptic fill-finish, and lyophilization to meet the needs of our global clients, particularly as biologics continue their strong growth trajectory.”
Just in November 2021, PCI announced the construction of a new clinical center of excellence in Bridgewater, MA, just 25 miles south of Boston. The investment allows for PCI to be closer to clients in the tri-state area, as well as just down the highway from some of the biggest pharmas in the world. That center is scheduled to be completed this summer, and will also add 50,000 square feet of operating space to its arsenal.